{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-000084","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2024-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.942992+00:00","generated_at":"2026-06-07T05:19:30.577963+00:00","sec_items":["1.01","2.02","3.02","8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Voyager Therapeutics enters $100M upfront collaboration with Novartis for SMA and HD gene therapy","bullets":["Voyager Therapeutics entered into a license and collaboration agreement with Novartis for AAV capsids for SMA and Huntington's disease programs, with $80M upfront payment and $20M stock purchase.","Voyager eligible for up to $200M in milestones for SMA program and $225M for HD program, plus sales milestones and tiered royalties.","Voyager estimates preliminary cash of $230.7M as of Dec 31, 2023; adjusted to $330.7M after anticipated $100M upfront from Novartis.","Voyager plans to submit IND for VY-TAU01 (Alzheimer's) in first half 2024 and for SOD1 ALS gene therapy in mid-2025.","Voyager entered into a stock purchase agreement and investor agreement with Novartis, including standstill and lock-up restrictions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-000084","json":"https://secwatch.observer/filing/0001104659-24-000084.json","markdown":"https://secwatch.observer/filing/0001104659-24-000084.md","text":"https://secwatch.observer/filing/0001104659-24-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/0001104659-24-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/tm241304d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:19:30.577963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"088fffea69a4bedfdb458b439637cfae0161261a","claim":"Voyager Therapeutics, Inc. entered into License and Collaboration Agreement with Novartis Pharma AG valued at $80 million (effective 2023-12-28).","evidence_excerpt":"On December 28, 2023 (the “Effective Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”) with Novartis Pharma AG (“Novartis”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465924000084/0001104659-24-000084-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Novartis Pharma AG"},{"label":"Value","value":"$80 million"},{"label":"Effective","value":"2023-12-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}